Leerink Swann started coverage on shares of Replimune Group (NASDAQ:REPL) in a research note published on Tuesday, Marketbeat.com reports. The firm issued an outperform rating and a $25.00 price target on the stock. Leerink Swann also issued estimates for Replimune Group’s Q1 2019 earnings at ($0.23) EPS, Q2 2019 earnings at ($0.17) EPS, Q3 2019 earnings at ($0.17) EPS, Q4 2019 earnings at ($0.17) EPS, FY2019 earnings at ($0.75) EPS, FY2020 earnings at ($1.31) EPS and FY2021 earnings at ($1.44) EPS.

Several other equities research analysts also recently issued reports on REPL. JPMorgan Chase & Co. started coverage on shares of Replimune Group in a research note on Tuesday. They set an overweight rating and a $26.00 price objective for the company. BMO Capital Markets started coverage on shares of Replimune Group in a research report on Tuesday. They set an outperform rating and a $31.00 target price on the stock.

REPL traded up $0.06 during trading on Tuesday, hitting $17.50. 600 shares of the company’s stock were exchanged, compared to its average volume of 84,007. Replimune Group has a 1 year low of $14.03 and a 1 year high of $17.90.

In other news, Director Joseph P. Slattery bought 6,667 shares of Replimune Group stock in a transaction dated Tuesday, July 24th. The shares were acquired at an average cost of $15.00 per share, with a total value of $100,005.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Fund Iv Gp L.P. Omega bought 266,667 shares of Replimune Group stock in a transaction dated Tuesday, July 24th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The disclosure for this purchase can be found here.

About Replimune Group

There is no company description available for Replimune Group Inc

Featured Article: Diversification

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.